“Budget Impact Analysis of Dabigatran Compared With Rivaroxaban in the Prevention of the Thromboembolic Risk in Patients With Non-Valvular Atrial Fibrillation”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 18, no. 1, Nov. 2017, https://doi.org/10.7175/fe.v18i1.1327.